Peter Fecci
Peter Edward Fecci is an American neurosurgeon, professor and researcher. He is an Associate Professor of Neurosurgery, Pathology and Immunology at Duke University School of Medicine. He also serves as Director of the Duke Center for Brain and Spine Metastasis, Director of the Brain Tumor Immunotherapy Program, Residency Program Director, and Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke. Fecci's research centers around brain tumor immunology and immunotherapy, and T cell dysfunction in glioblastoma and other intracranial cancers. Some of his research has dealt with clinical trial design for primary and metastatic  brain tumors, immunotherapeutic targeting of pituitary tumors, laser-induced interstitial thermal therapy (LITT), and novel nanotechnologies. He has published over 60 articles in scientific journals, and currently holds two active patents. In his practice as a neurosurgeon, he focuses on both primary and metastatic intracranial brain tumors. Fecci received the Sontag Distinguished Scientist Award in 2015, the Prince Mahidol Youth Mentor Award from the Prince Mahidol Award Foundation in 2016, the Duke Health Scholars Award in 2016, and was a National Institutes of Health visiting scholar in 2017. Education. Fecci received his Bachelor of Science degree in Neurobiology and Behavior  from Cornell University in 1999, followed by an M.D. and PhD from Duke University. His PhD thesis highlighted the role of regulatory T cells in restricting anti-tumor responses against glioblastoma. Career. After finishing his MD/PhD, Fecci started as an intern at Harvard Medical School’s Massachusetts General Hospital in 2007. He completed a Neurosurgical residency at Massachusetts General from 2008 to 2013. During his residency, he joined the Dana Farber Cancer Institute for a two-year post-doctoral fellowship. In 2014, Fecci joined Duke University Medical Center as an Assistant Professor in Neurosurgery, and was promoted to Associate  Professor in 2019. In 2014, he was appointed as the Director of the Brain Tumor Immunotherapy Program. He also became the Associate Program Director for Duke’s neurosurgical residency program in 2014 and assumed the role of Residency Program Director in 2019. He serves as the Director of the Third Year Medical Student Research Program in Neurosciences since 2015. In 2017, Fecci founded the Duke Center for Brain and Spine Metastasis and continues to serve as the Director of this Center. Research and work. Fecci has curated a body of research focused on brain tumor immunology and immunotherapy. In this  area, he wrote his first article in 2002 describing clinical immunotherapies for brain tumors. Towards the mid 2000s, his research began focusing on T cell dysfunction in brain tumor patients. In 2006, he published a paper entitled "Increased Regulatory T-cell Fraction Amidst a Diminished CD4 Compartment Explains Cellular Immune Defects in Patients with Malignant Glioma", in Cancer Research. He went on to publish multiple papers highlighting the role of regulatory T cells in restricting immunity and immune-based therapies for patients with brain tumors. Fecci has also contributed a body of work aimed at understanding the role of immune  checkpoints in mediating tumor immune escape in a variety of cancers. He was the first to explore immune checkpoint blockade as an immunotherapeutic strategy in brain tumor models: “Systemic blockade of CTLA-4 ameliorates glioma-induced changes to the CD4 T-cell compartment without affecting regulatory T-cell function” was published in Clinical Cancer Research in 2007. This was followed by a paper in 2012 exploring checkpoint blockade in combination with a tumor vaccine platform. In 2013, Fecci co-authored "Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors". Fecci and his colleagues demonstrated that "autochthonous  EGFR-driven lung tumors inhibit antitumor immunity by activating the PD-1/PD-L1 pathway to suppress T-cell function and increase levels of proinflammatory cytokines." Subsequently, Fecci conducted further research into the PD-1 / PD-L1 axis as an immunotherapy target in patients with cancer, co-authoring several subsequent papers on this topic in Nature Communications and Cancer Research. Fecci's research has gone on to produce entirely novel immunologic findings in cancer, including a 2018 "Nature Medicine" paper describing bone marrow T cell sequestration, a phenomenon exclusively accompanying cancers harbored within the intracranial compartment. His group is also the first  to clearly identify and characterize "bona fide" T cell exhaustion in glioblastoma, publishing these findings in "Clinical Cancer Research" in 2018. He has advocated for new approaches to categorizing and addressing T cell dysfunction in cancer, a viewpoint advanced in his 2018 Clinical Cancer Research review: "T cell dysfunction in glioblastoma: Applying a new framework." Through his lab, Fecci has worked on integrating strategies for reversing cancer-induced T cell dysfunction with current immune-based platforms. Fecci's lab has also worked on designing immune-based treatment programs for patients with primary or metastatic intracranial tumors. Their research focuses on  the limitations to immunotherapeutic success, more specifically on understanding and reversing T cell dysfunction in brain metastases and glioblastoma patients. In their earlier work, Fecci and his lab studied concerns for regulatory T cell-induced tolerance, with the focus shifting towards the study of T cell ignorance and exhaustion in the late 2010s. In the late 2010s, Fecci's research interests expanded to include attention to radiotherapy, stereotactic radiosurgery, radiation necrosis, and laser-induced interstitial thermal therapy (LITT) platforms.